Analytical Data
-
Gene name
HLA-A*02:01&B2M&GP100(YLEPGPVTA) Tetramer
- Application
-
Alternative Names
HLA0201; MHC I; gp100; Glycoprotein 100; ME20-M; P100
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-8*His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
A0A140T913 (G25-T305)&P61769
-
Expression Region
A0A140T913 (G25-T305)&P61769 (I21-M119)&YLEPGPVTA
-
Molecular Weight
260-265 kDa under Non reducing (N)
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The HLA-A*02:01&B2M&GP100(Tetramer) recombinant protein serves as a crucial tool in immunological research, particularly in the study of melanoma immunotherapy. HLA-A*02:01 is a prevalent human leukocyte antigen (HLA) class I molecule that presents peptide antigens to cytotoxic T lymphocytes (CTLs), enabling the immune system to recognize and eliminate cancer cells. The GP100 peptide, specifically YLEPGPVTA, is derived from the gp100 melanocyte differentiation antigen, which is often overexpressed in melanoma tumors. The combination of HLA-A*02:01, β2-microglobulin (B2M), and the GP100 peptide in tetrameric form allows for the precise identification and isolation of peptide-specific CTLs from peripheral blood samples. This tetramer system enhances our understanding of T-cell responses in melanoma patients and provides insights into the efficacy of therapeutic vaccines and adoptive T-cell transfer strategies. Additionally, by studying the interaction between T cells and the HLA-A*02:01/Gp100 complex, researchers can develop strategies to improve immune recognition of melanoma, paving the way for more effective immunotherapeutic approaches. Overall, the research on the HLA-A*02:01&B2M&GP100(Tetramer) recombinant protein is pivotal for advancing the field of cancer immunotherapy and improving clinical outcomes for patients with melanoma.
